chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia, Vomiting
Clinical narrative: This is a spontaneous report from a contactable nurse. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration on an unknown date in May2021 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included migraine, hashimoto's disease and patient was allergic to sulfa (sulfonamide). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on an unknown date in 2021 at 15:30 (at the age of 53-years-old) as a single dose for COVID-19 immunisation.  On 08May2021 at 03:00 the patient experienced fever highest 101.7, vomiting, muscle aches, cramping, headache, weak and tired. On same day the patient underwent body temperature and the result was 101.7 (unspecified unit). The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever highest 101.7, vomiting, muscle aches, cramping, headache, weak and tired were recovering at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Oral herpes
Clinical narrative: ''I'' got a fever blister on ''my'' lower lip; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 15Mar2021 at 11:45 (at the age of 56-years-old) and a second dose of BNT162b (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on an unknown date in 2021 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The medical history included slightly elevated cholesterol. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included cholesterol medication (unspecified) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received varicella zoster vaccine rge (cho) (SHINGRIX) for immunization on an unknown date. On 15Mar2021 at 17:00, the patient got a fever blister on his lower lip within 24 hours of the first injection and and also experienced same within 24 hours after the second injection. The patient reported that it was not occurred since he received shingrix (shingles vaccine) when he turned 50-year-old. So, for over 6 years, the patient did not have a fever blister and this leads to speculate him that this vaccine (suspect) may had reduce the efficacy of the shingles vaccine and this warrants further investigation. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were taken as a result of the reported event which included treatment with docosanol (ABREVA). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event fever blister on lower lip was resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: Red itchy dots on the forearm and elbow of left arm; red dots on left temple, some on back of neck and between shoulder blades; may be hives; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 19Mar2021 (at the age of 62-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) on an unknown date in 2021 (at the age of 62-years-old) both as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. The patient did not receive any concomitant medications. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date in 2021, the patient experienced red itchy dots on the forearm and elbow of left arm, red dots on left temple, some on back of neck and between shoulder blades, may be hives, still breaking out 4 weeks after shot, hives in earnest after second shot on 4/9. The events resulted in doctor or other healthcare professional office, clinic visit. Therapeutic measures were taken as a result of events hives and red itchy dots on the forearm and elbow of left arm, red dots on left temple, some on back of neck and between shoulder blades, may be hives, still breaking out 4 weeks after shot. The nurse practitioner looked at rash and treatment included doctor prescribed 1% cortisone cream, however the cream was helping just a little bit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events hives and red itchy dots on the forearm and elbow of left arm, red dots on left temple, some on back of neck and between shoulder blades, may be hives, still breaking out 4 weeks after shot were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 10Apr2021 at 14:45 (at the age of 56-year-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 01May2021 at 11:30 (at the age of 56-year-old); both as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and known allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included levothyroxine sodium (LEVOTHYROXIN) 0.05mg and unspecified vitamins; both for unspecified indication from an unknown date and unknown if ongoing. The patient previously took acetylsalicylic acid (ASPIRIN) for unspecified indication from an unknown date and experienced drug allergy. On 25Apr2021 at 09:00, the patient experienced ringing in ears which developed over the last 3-4 weeks (as reported). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event ringing in ears developed over the last 3-4 weeks was not resolved at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Heavy menstrual bleeding, Menstruation irregular
Clinical narrative: Heavy, irregular menstrual cycle; Heavy, irregular menstrual cycle; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the right arm on 22Apr2021 at 17:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included obesity and bee venom allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medication included phentermine (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. On 09May2021, the patient experienced heavy, irregular menstrual cycle. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events heavy, irregular menstrual cycle were unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Hypoaesthesia oral, Mouth swelling, Stomatitis, Throat irritation
Clinical narrative: Throat was burning; Edges of mouth are swollen; Edges of mouth are numb; Edges of mouth are irritated; Taste the chemicals in mouth; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05May2021 at 16:45 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not take any concomitant medication. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received naproxen (MANUFACTURER UNKNOWN) and diclofenac sodium (VOLTAREN) gel; on an unknown date for an unknown indication and experienced drug allergy. On 05May2021 at 17:00, after the shot was given, the patient started to taste the chemicals in her mouth. On 06May2021, next morning her throat was burning and the edges of her mouth were swollen, numb and irritated. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events taste the chemicals in mouth, throat was burning, edges of mouth were swollen, numb and irritated was not resolved at the time of the report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Parosmia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 49-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 08Apr2021 at 14:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 in the second week of Nov2020. The patient had no known allergies. Concomitant medication included birth control (unspecified) from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine.  The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Mar2021 at 14:00 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. On 15Apr2021 at 16:30, a few weeks later, the patient noticed that almost all of her food tasted different. The first time she really noticed was on Thursday (also reported as 15Apr2021), when she was drinking red wine and it tasted so different and it was not good. Since then, the patient had tried more red, as well as white wine and they did not taste good and tasted totally different. Most things that the patient ate and drank, did not taste the same. It tasted like nothing she could describe. The lemons smelled weird, cucumbers and red peppers tasted different. Tacos tasted weird and grilled burgers smelled weird. The patient wished that she could explain the taste and smell but it was nothing that can be described that was similar. It just smelled like bad food and the actual flavor that the patient used to taste, was very different. Almost like the food was going bad and was not sure if that was accurate. It just smelled and tasted worse than the flavor the food should be. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events noticed that almost all of food tastes different and lemons smell weird / grilled burgers smell weird was not resolved at the time of report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Chills, Fatigue, Headache, Myalgia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04May2021 at 16:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history lyme disease and known allergies to Bivalve. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included lyme disease vaccine (LYME), vitamin d nos (VIT D), retinol (VITAMIN A), ascorbic acid (VIT C), calcium (BUFFER C) and naltrexone (NALTREXONE), rhamnus cathartica/ rhamnus purshiana/ senna spp. (HERBAL), all for an unknown indication from an unknown dates and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Apr2021 at 16:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. On 05May2021, the patient experienced fatigue (Gr3), chills (Gr1), muscle aches (Gr2), headache (Gr1), nausea (Gr1), intestinal discomfort (Gr2). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events fatigue (Gr3), chills (Gr1), muscle aches (Gr2), headache (Gr1), nausea (Gr1), intestinal discomfort (Gr2) was recovered on an unknown date in May2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04May2021 at 16:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history lyme disease and known allergies to Bivalve. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included lyme disease vaccine (LYME), vitamin d nos (VIT D), retinol (VITAMIN A), ascorbic acid (VIT C), calcium (BUFFER C) and naltrexone (NALTREXONE), rhamnus cathartica/ rhamnus purshiana/ senna spp. (HERBAL), all for an unknown indication from an unknown dates and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Apr2021 at 16:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. On 05May2021, the patient experienced fatigue (Gr3), chills (Gr1), muscle aches (Gr2), headache (Gr1), nausea (Gr1), intestinal discomfort (Gr2). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events fatigue (Gr3), chills (Gr1), muscle aches (Gr2), headache (Gr1), nausea (Gr1), intestinal discomfort (Gr2) was recovered on an unknown date in May2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Cough, Dizziness, Fatigue, Headache
Clinical narrative: Fatgiue; Weakness; Headaches; Lightheadedness; Slight cough; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Mar2021 at 01:15 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included mononucleosis and Epstein Barr in 1996. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included finasteride (PROPECIA), fexofenadine hydrochloride (ALLEGRA) and cyanocobalamin, pyridoxine hydrochloride, thiamine hydrochloride (VITRON); all from unknown date for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021, the patient experienced fatigue and weakness, headaches, lightheadedness, slight cough. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had been tested for COVID-19. On 25Apr2021, the patient underwent Polymerase Chain Reaction (PCR) test for COVID- 19 via nasal swab and the result was negative. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fatigue and weakness, headaches, lightheadedness, slight cough was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Fatgiue; Weakness; Headaches; Lightheadedness; Slight cough; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Mar2021 at 01:15 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included mononucleosis and Epstein Barr in 1996. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included finasteride (PROPECIA), fexofenadine hydrochloride (ALLEGRA) and cyanocobalamin, pyridoxine hydrochloride, thiamine hydrochloride (VITRON); all from unknown date for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021, the patient experienced fatigue and weakness, headaches, lightheadedness, slight cough. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had been tested for COVID-19. On 25Apr2021, the patient underwent Polymerase Chain Reaction (PCR) test for COVID- 19 via nasal swab and the result was negative. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fatigue and weakness, headaches, lightheadedness, slight cough was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Hyperhidrosis, Pyrexia, Vomiting
Clinical narrative: 5 days after the 2nd vaccine experiencing sweats; 24 hours after the 2nd vaccine experienced vomitting; 24 hours after the 2nd vaccine experienced chills; 24 hours after the 2nd vaccine experienced fever; 24 hours after the 2nd vaccine experienced diarhea; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 06May2021 at 16:30 (at the age of 32-year-old), as a single dose for COVID-19 immunisation. Medical history included borderline thyroid and childhood asthma. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included unspecified vitamins and thyroid supplement; both for unknown indications from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 15Apr2021 at 16:45 (at the age of 32-year-old), as a single dose for COVID-19 immunisation. On 07May2021, 24 hours after the second vaccine, the patient experienced vomiting, chills, fever, diarrhea. On 10May2021, 5 days after the second vaccine the patient experienced sweats. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events vomiting, chills, fever, diarrhea and sweats was resolved with lasting effects on an unspecified date in May2021.  No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: Itching all over; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 19Apr2021 at 12:15 (at the age of 49-year-old) as a single dose for COVID-19 immunisation. Medical history included migraine  and chronic back pain. Prior to the vaccination, the patient was not diagnosed with COVID-19.The patient received unspecified medication within two weeks of vaccination. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On 20Apr2021 at 15:45, the patient experienced itching all over. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the event itching all over was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Hypoaesthesia oral, Pain in jaw, Paraesthesia oral
Clinical narrative: Tingling and numbness in my tongue; Tingling and numbness in my tongue; Left side of my jaw is painful and it hurts to open my mouth; Frequent headaches; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0172) via an unspecified route of administration in the left arm on 05May2021 at 08:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes in maternal grandfather and breast cancer in maternal grandmother. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ethinylestradiol / levonorgestrel (LARISSIA) for birth control from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 14Apr2021 at 08:30 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. On 05May2021 at 09:00, on the day of the second vaccine, the patient noticed tingling and numbness in the tongue. The patient noticed it first in maybe an hour after the shot and it remained numb and tingly for about 4-5 hours. It had since gone away, but left side of the jaw was painful, it was hurting when tried to open the mouth and had frequent headaches which the patient thought those were coming from the jaw pain. On the day of reporting, it had been 5 days since the shot and the patient still had jaw pain and was planning to see a doctor if there was no relief from the pain in the next few days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tingling and numbness in the tongue were resolved on 05May2021; while that of the events left side of the jaw was painful and it hurts to open the mouth and frequent headaches were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Headache, Pyrexia, SARS-CoV-2 test
Clinical narrative: headache; Fatigue; Fever 101; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the right arm on 27Apr2021 at 18:45 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the right arm on 06Apr2021 at 18:45 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. On 27Apr2021, the patient experienced headache, fatigue and fever 101. On the same day, the patient underwent body temperature test and the result was 101 (unspecified units). On 03May2021, the patient underwent PCR test (nasal swab) and the result was negative. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events headache, fatigue and fever 101 was resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain, Vertigo
Clinical narrative: Next day for 3 days very bad body pain; Day 4-5 extreme fatigue; Day 4-5 extreme vertigo.; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 05May2021 at 17:45 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included hashimoto's, sjogrens and allergic to penicillin. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included thyroid (ARMOUR THYROID) and hydroxychloroquine sulfate (PLAQUENIL); both were taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 14Apr2021 at 17:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. On 06May2021 at 10:00, next day for 3 days, the patient experienced very bad body pain. On an unknown date in May2021, day 4-5, the patient experienced extreme fatigue and vertigo. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether any therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events next day for 3 days very bad body pain and day 4-5 extreme fatigue and vertigo were unknown at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Migraine, Vision blurred
Clinical narrative: Migraines; Obscured vision, difficulty reading; This is a spontaneous report from a contactable consumer, the patient. A 20-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the arm right on 07Apr2021 at 12:45 (at the age of 20-year-old) and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0167) via an unspecified route of administration in the arm right on an unknown date in 2021 (at the age of 20-year-old) both as a single dose for COVID-19 immunisation. The patient did not have any medical history and known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medication within two weeks prior to the vaccination. On 14Apr2021 at 10:00, the patient experienced migraines almost daily, obscured vision and reading difficulty. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events migraines almost daily, obscured vision and reading difficulty was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Headache, Myalgia, Nausea
Clinical narrative: Headache; Muscle pain; Nauseas; Dizzied; Extremely tired; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ew0179) via an unspecified route of administration in the arm right on 08May2021 at 11:45 as a single dose for COVID-19 immunisation. Medical history was not reported.  Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) taken for an unknown indication from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the arm right on 17Apr2021 at 11:45 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10May2021 at 00:00, the patient experienced headache, muscle pain, nausea, dizzied and felt extremely tired. The events did not result in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.The clinical outcome of the events headache, muscle pain, nauseas, dizzied and extremely tired were not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Tinnitus
Clinical narrative: Tinnitus; Joint pain; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 25Mar2021 at 12:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. The medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included omeprazole (MANUFACTURER UNKNOWN), fish oil (MANUFACTURER UNKNOWN) and unspecified multivitamins; all from unknown dates for unknown indications and unknown if ongoing. On 31Mar2021, the patient experienced tinnitus, joint pain and fatigue. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tinnitus, joint pain and fatigue were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Migraine, Nausea
Clinical narrative: Extreme Migraine; Nausea; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0183) via an unspecified route of administration on 08May2021 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included triamcinolone acetonide (NASACORT) and oxymetazoline (AFRIN); for an unknown indication, on an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration on 17Apr2021 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. On 09May2021 at 10:00, the patient experienced extreme migraine, nausea and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit/ emergency visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of adverse events. The clinical outcome of the events extreme migraine, nausea and fatigue was recovered on an unknown date in May2021.  No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness, Peripheral swelling
Clinical narrative: Swelling in the fingers of my left hand.; Unable to bend fingers back up for a few hours; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Mar2021 at 11:30 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety, depression, and migraines. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included vilazodone hydrochloride (VIIBRYD), topiramate (TROKENDI), quetiapine fumarate (SEROQUEL); all for unknown indication from unknown date and unknown if ongoing and botulinum toxin type a (BOTOX) for migraines from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021, the patient experienced swelling in the fingers of her left hand. Mostly in morning, she was unable to bend fingers back up for a few hours. It would go away after a while during the day and return again at night. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event swelling in the fingers of left hand; mostly in morning, unable to bend fingers back up for a few hours; it would go away after a while during the day and return again at night was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Crying, Impaired work ability, Insomnia
Clinical narrative: Severe fever; Shivering for 24 hours; Unable to sleep or do anything else / Didn't do anything except lay in bed and try to sleep for 24 hours; Unable to sleep or do anything else; Pain all over, Pain enough to make me lay in bed; Pain all over, every joint; Pain all over, every joint, every muscle; Pain enough to make me lay in bed and cry for hours; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO176) via an unspecified route of administration in the right arm on 08May2021 at 12:15 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome with constipation (IBS-C). The patient's allergies included asthma from eggs, nothing else. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included sertraline (MANUFACTURER UNKNOWN) daily, taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 17Apr2021 at 13:00 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. On 09May2021 at 00:00, the patient experienced severe fever, shivering for 24 hours, unable to sleep or do anything else, pain all over, every joint, every muscle. It started at midnight the day of the vaccination and continued until midnight of 10May2021, the following day. Pain enough to make the patient lay in bed and cry for hours. Did not do anything except lying in bed and tried to sleep for 24 hours. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe fever, shivering, unable to sleep or do anything else, pain all over, every joint, every muscle, pain enough to make the patient lay in bed and cry for hours and did not do anything except lying in bed and tried to sleep for 24 hours was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pain, Pyrexia
Clinical narrative: Severe fever; Shivering for 24 hours; Unable to sleep or do anything else / Didn't do anything except lay in bed and try to sleep for 24 hours; Unable to sleep or do anything else; Pain all over, Pain enough to make me lay in bed; Pain all over, every joint; Pain all over, every joint, every muscle; Pain enough to make me lay in bed and cry for hours; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO176) via an unspecified route of administration in the right arm on 08May2021 at 12:15 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome with constipation (IBS-C). The patient's allergies included asthma from eggs, nothing else. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included sertraline (MANUFACTURER UNKNOWN) daily, taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 17Apr2021 at 13:00 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. On 09May2021 at 00:00, the patient experienced severe fever, shivering for 24 hours, unable to sleep or do anything else, pain all over, every joint, every muscle. It started at midnight the day of the vaccination and continued until midnight of 10May2021, the following day. Pain enough to make the patient lay in bed and cry for hours. Did not do anything except lying in bed and tried to sleep for 24 hours. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe fever, shivering, unable to sleep or do anything else, pain all over, every joint, every muscle, pain enough to make the patient lay in bed and cry for hours and did not do anything except lying in bed and tried to sleep for 24 hours was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Pain, Pain in extremity, Vaccination site pain
Clinical narrative: Pain is stabbing and piercing whenthe arm is activated; Pain directly at the injection site whichis very localized and under the skin; Most pain comes up in the shoulderjoint. Sometimes pain is felt in or travels to the elbow joint.; Pain when the arm is not used isabout 4/10 and enough to wake patient up at night; This is a spontaneous report from a contactable healthcare professional. A 55-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration in the left arm on 04Mar2021 at 15:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. It was unknown whether the patient had received any other vaccines within four weeks prior to the vaccination. It was unknown whether the patient had any concomitant medications within two weeks of vaccination. On 05Mar2021 at 15:30 the patient experienced stabbing pain and piercing when the arm was activated. The patient reported of "pain directly at the injection site which was very localized and under the skin, most pain comes up in the shoulder joint, sometimes pain is felt in or travels to the elbow joint, pain when the arm was not used was about 4/10 and enough to wake patient up at night". The patient experienced pain when doing the wrong movement "it was up to 7/10 and unbearable". This pain only lasted for seconds. It was reported that the patient had a lingering pain when not activated which feels like a tired "overused" joint and pressing on the rotator cuff tendon brought up the pain also the patient could not use his arm for normal physical work. There was no redness or lump around it and was never been. There were no secondary contributing factors like accidental injury and otherwise, patient was feeling quite well. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with ibuprofen (MANUFACTURER UNKNOWN). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events pain is stabbing and piercing when the arm was activated, pain directly at the injection site which was very localized and under the skin, most pain comes up in the shoulder joint, sometimes pain was felt in or travels to the elbow joint and pain when the arm was not used is about 4/10 and enough to wake patient up at night were resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Total lung capacity, Total lung capacity decreased
Clinical narrative: Burning in chest while exercising; Reduced lung capacity; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 20Apr2021 at 12:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history and allergies were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive any medication within two weeks of vaccination. On 21Apr2021, at 16:00, the patient experienced burning in chest while exercising and reduced lung capacity. On21Apr2021, the patient underwent total lung capacity test and the result was found to be reduced. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events burning in chest while exercising and reduced lung capacity. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events burning in chest while exercising and reduced lung capacity was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.